Loading...
Market
First AI-developed drug candidate from Eli Lilly and OpenAI collaboration?
5
Resolution / Starting Odds
Antimicrobial for MRSA • 25%
Antimicrobial for VRE • 25%
Antimicrobial for CRE • 25%
Other • 25%
Official press release from Eli Lilly or major news outlets
Story
Eli Lilly ($LLY) Collaborates with OpenAI to Develop Medicines for Drug-Resistant Bacteria
Jun 25, 2024, 02:04 PM
Eli Lilly ($LLY) has announced a collaboration with OpenAI to leverage generative AI in the discovery of novel medicines aimed at treating drug-resistant bacteria. This partnership aims to accelerate the development of new antimicrobials to combat antimicrobial resistance (AMR), which is considered one of the top public health threats globally. Dave Ricks, CEO of Eli Lilly, emphasized that this collaboration is a significant step forward in the fight against antimicrobial resistance, combining the expertise of Lilly's scientists with OpenAI’s advanced AI platform. Diogo Rau, EVP & chief information and digital officer at Lilly, stated that generative AI opens new opportunities for custom, purpose-built technologies in this battle. The initiative also supports Lilly's earlier commitment to addressing drug-resistant pathogens through its Social Impact Venture Capital Portfolio, which includes the AMR Action Fund.
View original story
Similar markets
Machine Learning • 25%
Deep Learning • 25%
Natural Language Processing • 25%
Other • 25%
Insilico Medicine • 25%
Amgen • 25%
Nested Therapeutics • 25%
Other • 25%
Insilico Medicine • 25%
Amgen • 25%
Terray Therapeutics • 25%
Other • 25%
Yes, identified and announced • 33%
Yes, identified but not announced • 33%
No, not identified • 33%
No new partnerships • 33%
1-2 new partnerships • 33%
More than 2 new partnerships • 33%
Cancer • 25%
Cardiovascular disease • 25%
Neurological disorder • 25%
Other • 25%
Yes • 50%
No • 50%
Google DeepMind • 25%
Microsoft • 25%
IBM • 25%
Other • 25%
Yes • 50%
No • 50%
Cardiovascular • 25%
Oncology • 25%
Neurology • 25%
Other • 25%